Fig. 4.
Fig. 4. Analysis of organ weights in the Epo-TAghand healthy mice at the end of the experiment. / Healthy mice, Epo-TAgh mice, healthy mice treated with AAV-CMVGFP, Epo-TAgh mice treated with AAV-CMVGFP, healthy mice treated with AAV-CMVEpo, Epo-TAgh mice treated AAV-CMVEpo, healthy mice treated with AAV-HREEpo, Epo-TAgh mice treated AAV-HREEpo. Average weights of organs are plotted ± SD (n = 4-6). Spleens in the AAV-CMVEpo–treated groups are significantly enlarged. Hearts of Epo-TAgh mice are enlarged compared with those of healthy mice. This enlargement was partially reversed after treatment with the AAV-HREEpo vector that physiologically corrected the hematocrit. In this experiment, AAV-CMVEpo–treated mice were culled on day 76, and all other mice were culled on day 218.

Analysis of organ weights in the Epo-TAghand healthy mice at the end of the experiment.

Healthy mice, Epo-TAgh mice, healthy mice treated with AAV-CMVGFP, Epo-TAgh mice treated with AAV-CMVGFP, healthy mice treated with AAV-CMVEpo, Epo-TAgh mice treated AAV-CMVEpo, healthy mice treated with AAV-HREEpo, Epo-TAgh mice treated AAV-HREEpo. Average weights of organs are plotted ± SD (n = 4-6). Spleens in the AAV-CMVEpo–treated groups are significantly enlarged. Hearts of Epo-TAgh mice are enlarged compared with those of healthy mice. This enlargement was partially reversed after treatment with the AAV-HREEpo vector that physiologically corrected the hematocrit. In this experiment, AAV-CMVEpo–treated mice were culled on day 76, and all other mice were culled on day 218.

Close Modal

or Create an Account

Close Modal
Close Modal